Slide Deck

View the most recent Company Presentation.

Overview

See the most recent company overview and technical summary below.

Fact Sheet

Capital Structure

Shares Issued:

9,250,000

Management/Insider Ownership:

3,2 M (35%)

Warrants:

1,000,000

Authorized:

250,000,000 Common

100,000,000 Preferred

Check out some of the media and interesting articles on our technology assets and the related biotech and healthcare sectors.


Articles and Media

Video Interview with CEO Denis Corin

Business Television CEO Clip

PODCAST - BioReport with Danny Levin

The embattled pharma executive Martin Shkreli, whether intentional or not, has ignited a long smoldering public policy discussion about the pricing of pharmaceuticals.  We spoke to Denis Corin, CEO of Q BioMed, an acceleration and development company, for a perspective on the fallout from Shkreli, how to balance innovation with affordability, and whether he expects any lasting impacts on small drug developers.

Forward-Looking Statement

This website includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of our management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; dependence on the effectiveness of any patents we acquire and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The information contained in this website was current as of the date presented. We assume no duty to update the information to reflect subsequent developments. Consequently, we will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

We do not control the websites that you may be linked to by our website.  Once you leave QBioMed.com, we do not control the content that you will be exposed to and cannot vouch for its accuracy or completeness.  We do not endorse any statements on such websites or take responsibility for your reliance on the information contained therein.

Social media & sharing icons powered by UltimatelySocial